Condition
Multiple Myeloma Stage I
Total Trials
3
Recruiting
0
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 3 (2)
Trial Status
Active Not Recruiting1
Terminated1
Unknown1
Clinical Trials (3)
Showing 3 of 3 trials
NCT03428373Phase 2Active Not Recruiting
Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma
NCT03792620Phase 3UnknownPrimary
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation
NCT00171925Phase 3TerminatedPrimary
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Showing all 3 trials